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Abstract: The hepatitis B virus (HBV) is a global problem; however, the burden of HBV infection in
pregnant women in Botswana is unknown. We sought to determine the prevalence of chronic and
occult HBV infection in human immunodeficiency virus (HIV)-infected and -uninfected pregnant
women in Botswana. Samples from 752 pregnant women were tested for hepatitis B surface antigen
(HBsAg), and HBsAg-positive samples were tested for hepatitis B e antigen (HBeAg) and HBV DNA
load. Samples that were HBsAg negative were screened for occult HBV infection by determining the
HBV DNA load. HBV genotypes were determined based on a 415-base-pair fragment of the surface
gene. Among the 752 women tested during pregnancy or early postpartum, 16 (2.1%) (95% confidence
interval (CI): 2.0–2.2) were HBsAg-positive. The prevalence of chronic HBV infection was higher
(3.1%) among HIV-infected (95% CI: 3.0–3.2) compared with HIV-uninfected women (1.1%) (95% CI:
1.07–1.1, p = 0.057). Among the 622 HBsAg-negative women, the prevalence of occult HBV infection
was 6.6% (95% CI: 6.5–6.7). Three of thirteen HBsAg-positive participants were HBeAg-positive,
and all were HIV-negative. Of the 11 maternal samples successfully genotyped, five (45.5%) were
genotype D3, five (45.5%) were genotype A1, and one was genotype E (9%). Low and similar
proportions of HIV-infected and -uninfected pregnant women in Botswana had occult or chronic
HBV infection. We identified a subset of HIV-negative pregnant women who had high HBV DNA
levels and were HBeAg-positive, and thus likely to transmit HBV to their infants.
Keywords: pregnant women; hepatitis B virus (HBV); human immunodeficiency virus (HIV); Botswana
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1. Introduction
Viral hepatitis is a major cause of morbidity and mortality, and it is ranked as the seventh-leading
cause of mortality in the world [1]. Hepatitis B virus (HBV) infection causes 70% of the viral
hepatitis-related mortality [2]. Global estimates suggest that 3.6% of the world’s population is infected
with HBV [3], with the highest burden in Asia and sub-Saharan Africa [4,5]. Human immunodeficiency
virus (HIV) and HBV are significant public health threats in sub-Saharan Africa. It is well documented
that HIV/HBV coinfection impacts the natural progression of HBV infection, resulting in increased
HBV transmission and decreased host immune responses [6–8].
In most highly HBV-prevalent regions, the majority of HBV infections occur in early childhood,
either through vertical or horizontal transmission [9]. HBV infection during early childhood is more
likely to result in chronic HBV infection [10,11] compared to infection occurring later in life. While
considerable focus has been made on reducing the vertical transmission of HIV in sub-Saharan
Africa, research on the prevention of HBV vertical transmission in sub-Saharan Africa is quite limited.
Therefore, there is a need to generate country-specific data to determine the rates of HBV infection in
pregnant women and children and to evaluate if the intensification of HBV prevention strategies is
needed within the country.
Botswana, a southern African country with a population of approximately 2.3 million, has an
intermediate prevalence of HBV [12]. The country also has one of the highest prevalence of HIV
globally, at 18.5% [13]. There is scant data on HBV prevalence in Botswana, with most of the available
data coming from HIV-infected cohorts in whom HBV prevalence ranges between 5% and 10% [4,14,15],
including in HIV-infected pregnant women [16]. Data regarding HBV prevalence in HIV-uninfected
pregnant women is nonexistent in Botswana. We sought to determine the prevalence of chronic and
occult HBV infection in HIV-infected and -uninfected pregnant women in Botswana.
2. Materials and Methods
2.1. Study Participants
We used stored samples and existing data from the completed Tshipidi study that has been
described in detail previously [17]. Briefly, Tshipidi was a prospective cohort study that enrolled and
followed 453 HIV-infected and 457 HIV-uninfected pregnant women and their live-born infants at two
sites (the city of Gaborone and the village of Mochudi) in Botswana from 2010 to 2012. Mothers and their
infants were followed to evaluate the effects of in utero exposure to maternal HIV or to antiretroviral
drugs on neurodevelopment and child health outcomes at two years of age. For the current study,
samples from all mothers at delivery (and also at enrollment for the chronic HBV-positive participants)
were included, provided that the relevant stored sample(s) were still available. The delivery samples
were drawn at least two months apart from the enrollment samples.
Tshipidi study participants provided written informed consent for study participation. The study
was done in accordance with the Declaration of Helsinki, and the research protocol was approved
by the Health Research Development Committee at the Botswana Ministry of Health and Wellness
(HRDC00524) and the Office of Human Research Administration at the Harvard T.H. Chan School of
Public Health (18093).
2.2. Hepatitis B Virus Serological Screening
Available Tshipidi plasma samples were tested for hepatitis B surface antigen (HBsAg) using
a Murex HBsAg kit (Murex Biotech, Dartford, UK). The positive samples were repeated to validate
their positive status using the Murex HBsAg kit. The samples that were positive for HBsAg were
screened for hepatitis E antigen (HBeAg) using the Monolisa HBeAg-Ab PLUS kit (Bio-Rad, Hercules,
CA, USA).
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2.3. Hepatitis B Virus DNA Levels
Maternal samples were tested for HBV DNA levels. HBsAg positive samples were also tested
at the enrollment visit. HBV DNA levels were quantified using the COBAS® AmpliPrep COBAS®
Taqman®, HBV Test v.2.0 (Roche diagnostics, Mannheim, Germany) following the manufacturer’s
instructions. The limit of detection was 20 IU/mL. HBV DNA suppression was defined as undetectable
(not detected or ND) HBV DNA.
2.4. DNA Extraction for Genotyping
DNA was extracted from 200 µL of plasma samples using the QiAmp DNA extraction kit
according to the manufacturer’s protocol (QIAGEN, Hilden, Germany). An elution volume of 50 µL
was used instead of the 200 µL recommended in the protocol to increase sample concentration. DNA
extracts were either used for amplification directly or stored at −80 ◦C until use.
2.5. HBV Genotyping
Chronic HBV positive samples were genotyped using a previously published protocol [18]. Briefly,
a 415-base-pair (bp) fragment of the surface gene was amplified using a seminested polymerase chain
reaction (PCR) using the SuperScript™ III One-Step RT-PCR System with Platinum® Taq High Fidelity
(Life technologies, Waltham, MA, USA). Primers HBV381 (5’-GTTTAAATGTATACCCAAAGAC-3’;
nt 840–861) and HBV840 (5’-TGCGGCGTTTTATCATCTTCCT-3’; nt 381–402) were used for
the first round of PCR, with cycling conditions as previously described [4]. HBV801
(5’-CGACGGCATAAAGGGACTCAAG-3’: nt 801–822) and HBV381 were used for the second round [4].
A 2% agarose gel stained with ethidium bromide was used to view the PCR product. The PCR
products were cleaned using the QIAquick® PCR purification kit (QIAGEN, Mannheim, Germany).
Primers HBV801 and HBV381 were used for the sequencing reactions. DNA was labeled using ABI
BigDye® v3.1 terminators (Applied Biosystems, Foster City, CA, USA) and purified using ZR DNA
Sequencing Clean-up Kit™ (Zymo, Irvine, CA, USA) as per manufacturers’ protocol. The sequencing
chromatograms were created using an ABI 3130xl genetic analyzer (Applied Biosystems).
Chromatographs were edited using Sequencher version 5.0 [19] to generate consensus sequences.
Nucleotide alignments were performed with Clustal X 2.1 [20]. Representative references of genotypes
A–H were retrieved from GenBank and aligned with sequences from this study to determine genotypes.
The National Center for Biotechnology Information (NCBI) GenBank accession numbers for sequences
found in this study are MG977689, MG977690, MG977693, MG977694, MG977695, MG977696,
MG977697, MG977698, MG977699, MG977700, and MG977701. Additional phylogenetic inference
was performed using a Bayesian Markov chain Monte Carlo (MCMC) approach as implemented in
the Bayesian evolutionary analysis by sampling trees (BEAST) version 1.8.4 program [21], with an
uncorrelated log-normal relaxed molecular clock, general time-reversible model, and nucleotide site
heterogeneity estimated using a gamma distribution. The MCMC analysis was run for a chain length
of 100,000,000, and results were visualized to confirm adequate chain convergence with Tracer version
1.6 [22]. The effective sample size (ESS) was calculated for each parameter, and all ESS values were
>500, indicating sufficient sampling. The maximum clade credibility tree was selected from the
posterior tree distribution after a 10% burn-in using Tree Annotator version 1.8.4 [21] and visualized in
FigTree version 1.4.3 [23]. Posterior probabilities >0.90 are noted as statistically significant, as described
previously [24,25].
2.6. Data Analysis
Chronic HBV infection was defined as HBsAg positivity, while occult HBV infection was defined
as HBsAg negativity, but with detectable HBV DNA. Data were reported using proportions, medians,
and interquartile ranges (IQR). Categorical and continuous characteristics were compared by HBV
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status using Fisher’s exact test or Wilcoxon’s rank sum test, respectively. All data were analyzed using
STATA v14.0 [26], and p-values <0.05 were considered statistically significant.
3. Results
Of 912 mothers that were enrolled in the parent cohort, 752 were screened for HBsAg (chronic
HBV infection), and 622 out of the 752 were screened for occult HBV infection (i.e., HBsAg-negative
with detectable HBV DNA). Samples from participants with positivity for the HBsAg results were
tested for HBeAg, and the HBV-positives were genotyped as per Figure 1.
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Figure 1. Screening algorithm showing the different tests that were performed and the results obtained.
HBsAg: hepatitis B surfac antigen, HBeAg: hepatitis B e antigen, HBV: hepatitis B virus, ND: not detectable,
*: all these were HBsAg-positive.
Of the 912 women, 454 were HIV-infected and 458 HIV-uninfected. Of the 752 women, 384 are
HIV-positive and 368 are HIV-negative. The median CD4+ T-cell counts of the HIV-positive maternal
participants were 422 (313, 567), 460 (340, 511), 604 (322, 616), 418 (313, 563), and 481 (289, 628) for
the chronic HBV-positive, occult HBV-positive, HBV-negative, and the total HBV-positive groups,
respectively. The aspartate transaminase (AST), alanine transaminase (ALT), HIV status, HIV viral
load, and other characteristics were not significantly different between the different groups (Table 1).
The prevalence f HBV infection in pregnant women was 2.1% (16/752), and 6.6% (41/622) for
chronic and occult HBV infection, resp ctively. Chro ic HBV positivity was significantly higher in
HIV-positive women (3.1%; 12 of 384) compared to HIV-negative women (1.1%; 4 of 368; p = 0.057),
as shown in Figure 2. However, there was no difference in occult HBV infection in HIV-negative women as
compared to HIV-positive women (24 (7.4%) of 323 versus 17 (5.7%) of 299 women, respectively (p = 0.38)).
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Table 1. Association of clinical demographics with chronic versus occult hepatitis B virus (HBV) infection.
All
(N = 752)
Chronic HBV
(N = 16)
Occult HBV
(N = 41) p-Value
Chronic or Occult HBV
(N = 57)
HBV-Negative
(N = 695) p-Value
Media maternal age in years (n = 581)
(Q1, Q3) 27 (24, 32) 29 (25, 33) 28 (23, 32) 0.58 27 (23, 31) 27 (23, 32) 0.24
HIV-positive women 384 * and 299 + 12 (3.1%) 17 (5.7%) 0.057 a 29 (7.6%) 355 (92.4%) 0.54
HIV-negative women 368 * and 323 + 4 (1.1%) 24 (7.4%) 0.38 b 28 (7.6%) 340 (92.3%)
HIV viral load (copies/mL) (Q1, Q3) 1549.5 (400, 13,808) 508.5 (193, 3819) 1568 (395, 9635) 0.70 676 (400, 7762) 1585 (400, 14,125) 0.16
CD4+ T-cell count (cells/µL) (Q1, Q3) 422 (313–567) 460 (340, 511) 604 (322, 616) 0.14 481 (289, 628) 418 (313, 563) 0.25
Platelet count (Q1, Q3) 267 (216–311) 296 (211, 365) 272 (228, 371) 0.18 298 (233, 371) 265 (211, 309) 0.52
Hemoglobin (g/dL) (Q1, Q3) 11 (10–12) 12 (11, 12) 11 (9.0, 12) 0.19 12 (10, 13) 10.9 (9, 12) 1.00
ALT (U/L) (Q1, Q3) 13 (11, 19) 12 (10, 13) 14 (12, 19) 0.74 13 (10, 14) 13 (11, 17) 0.65
AST (U/L) (Q1, Q3) 23.4 (19, 30) 24 (18, 30) 22 (18, 30) 0.30 30 (21, 35) 23 (19, 30) 0.35
Total bilirubin (µmol/L) (Q1, Q3) 6 (4, 8) 4 (2.9, 5.7) 4.7 (4, 12) 0.10 4 (3, 6) 6 (4, 8) 1.00
HIV: Human immunodeficiency virus, ALT: Alanine transaminase, AST: Aspartate transaminase, Q1; first quartile, Q3: third quartile,*: totals for participants tested for chronic HBV
infection, +: totals for participants tested for occult HBV infection, a: p-value for chronic infection in the HIV-positive women versus HIV-negative women, b: p-value for occult infection in
HIV-positive versus HIV-negative women.
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HBsAg-positive women who were HIV-negative had HBV DNA levels between 396 IU/mL and >
1.70× 108 IU/mL, and three out of four were HBeAg. Of the 13 participants with chronic HBV infection,
three were HBeAg-positive and all were HIV-negative. These three participants had HBV DNA levels >
1.7 × 108 IU/L at both enrolment and delivery. The delivery samples were drawn at least two months
apart from the enrollment samples. All 12 HIV-positive chronically infected participants had HBV DNA
levels between < 20 IU/mL and 12,900 IU/mL. Of these women, 58.3% (7/12) were on Zidovudine
(AZT) monotherapy and 41.7% (5/12) were on highly active antiretroviral therapy (HAART).
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Figure 2. Prevalence of occult and chronic HBV infection amongst the human immunodeficiency virus
(HIV) positive and HIV negative pregnant women.
We then evaluated the prevalence of HBV infections amongst HIV-positive participants with a
CD4+ T-cell count of > 500 cells/mL and thos with a CD4+ T cell cou of ≤ 500 c lls/mL. This was to
determine if there is an ass ciatio of BV infection wit CD4+ T-cell counts in HIV-i fected participants.
Of the 384 tested for chronic HBV infection, 382 had available CD4+ T-cell count results, and of
the 299 tested for occult HBV infection, 297 had available CD4+ T-cell count results. Amongst the 382
tested for chronic HBV infection, 129 had CD4+ T-cell counts of > 500 cells/mL and 253 had CD4+
T-cell counts of≤ 500 cells/mL. Amongst the 129 with CD4+ T-cell counts of > 500 cells/mL, three were
chronically HBV-infected, and out of the 253 with ≤ 500 cells/mL, nine were chronically HBV-infected,
yielding a chronic HBV infection prevalence of 3/129 (2.33%) and 9/253 (3.56%), respectively. For the
297 tested for occult HBV infection, 96 had CD4+ T-cell counts of > 500 cells/mL and 201 had CD4+
T-cell cou ts of ≤ 500 cells/mL. Amongst the 96 with CD4+ T-cell counts of > 500 cells/mL, 10 had
occult HBV infection, a d of the 201 with CD4+ T-cell ounts of ≤ 500 cells/mL, seven had occult HBV
infection, yielding an occu t HBV infection preval nce of 10/96 (10.4%) a d 7/201 (3.48%), respectively.
There was a signific t difference i the prevalence of occult HBV infection in w men with
CD4+ T-cell counts of > 500 cells/mL compared to those with a CD4+ T-cell count of ≤ 500 cells/mL
(p-value = 0.01). Of the participants that were on treatment (n = 267), 96 had a CD4+ T-cell count of >
500 cells/mL (three of whom were receiving unspecified anti retroviral therapy, ART) and 171 had a
CD4+ T-cell count of ≤ 500 cells/mL (four of whom were receiving unspecified ART). There was no
difference in the CD4+ T-cell counts in women taking AZT or HAART.
Of the 16 chronic HBV infections, 11 (69%) samples were successfully genotyped (Table 2).
Five samples (45.5%) were genotype D, five (45.5%) were genotype A, and one was genotype E (9%).
Figure 3 shows the clustering of the different genotypes with the genotype references. All the sequences
cluster with sequences from Botswana and other African countries. One genotype D sequence had a
T131N immune escape mutation.
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Table 2. HBV DNA levels at enrollment and delivery, and HBeAg status for the 16 women with chronic HBV infection (HBsAg-positive).
Participant Code HBV DNA at Enrollment (IU/L) HBV DNA at Delivery (IU/L) HBeAg at Delivery HIV Status ART Regimen Genotype
TAM 1 NT ND NEG POS AZT D
TAM 2 NT ND NEG POS AZT A
TAM 5 8710 ND NEG POS AZT A
TAM 6 <20 ND NEG POS CBV + NVP A
TAM 7 <20 2250 NEG POS AZT A
TAM 8 >1.70 × 108 >1.70 × 108 POS NEG NA D
TAM 9 >1.70 × 108 >1.70 × 108 POS NEG NA A
TAM 10 >1.70 × 108 >1.70 × 108 POS NEG NA D
TAM 11 170 396 NT NEG NA E
TAM 12 NT 12,900 NT POS AZT D
TAM 13 NT ND NT POS NVP ± TRU D
TAM 14 25 ND NEG POS CBV + NVP NA
TAM 15 24.8 <20 NEG POS ATR NA
TAM 16 237 ND NEG POS CBV + NVP NA
TAM 17 82 166 NEG POS AZT NA
TAM 18 ND 2300 NT POS AZT NA
AZT: zidivodine; NA: not applicable; NT: not tested; ND: target not detected; HAART: highly active antiretroviral therapy. The women were on different HAART combinations, including
Combivir (CBV) + Nevirapine (NVP) and Truvada (TRU) + Nevirapine, as well as Atripla (ATR) alone.). NEG: negative; POS: positive; TAM: participant unique code.
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Figure 3. Bayesian phylogenetic analysis of S gene sequences (indicated by participant code (TAM
number) compared to reference sequences (indicated by their subgenotypes, accession number, and
country of origin). HBV genotype A sequences (n = 5) are shown in red, genotype D sequences (n = 5)
in blue, and genotype E sequences (n = 1) in green.
4. Discussion
In this study, we present the largest analysis of both chronic and occult HBV infection prevalence
in HIV-infected and HIV-uninfected pregnant women in Botswana, a sub-Saharan African country with
high prevalence of HIV and an intermediate prevalence of HBV. The chronic and occult HBV infection
prevalence in the pregnant women was 2.1% and 6.6%, respectively, and there was no difference
between the prevalence rates in the HIV-positive and HIV-negative participants. The median age of
the pregnant women was 27 years, and age did not seem to be a risk factor for HBV infection as there
was no difference in ages of the women with HBV versus those without HBV. However, a recent study
in Uganda reported higher rates of new HBV infections among HIV-infected patients, which were
drastically reduced by initiation of combination antiretroviral therapy (cART) [27]. Other studies in
Botswana have reported similar prevalence rates, although these studies included only HIV-infected
individuals [4,16]. Higher prevalence rates have been reported by others in the region, ranging from
6.9% to 11.6% [28–30].
Occult HBV infection prevalence reported in this study is lower than the findings by Ryan et al.,
who reported a prevalence of 26.5% in HIV-positive patients in Botswana at baseline [31]. Although
the results of our study show a lower prevalence of occult HBV infection compared to the prevalence
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found by Ryan et al. in HIV-infected treatment-naïve patients, our results are comparable with those
from the same study after the participants had initiated cART (1.5%) [31].
HIV-positive women with chronic HBV infection had lower HBV DNA levels compared to the
HIV-negative women at both enrollment and delivery visits. Three out of four HIV-negative women
had positive HBeAg results and high HBV DNA levels. High HBV DNA and HBV E antigen (HBeAg)
positivity are risk factors for HBV vertical transmission; therefore, there is a likelihood of passing on
the infection as these women are not taking any anti-HBV drugs [32]. HBsAg positivity and non-occult
infection has been linked to vertical transmission [33,34]. These findings are concerning, as HBV is not
part of the antenatal screening tests done in Botswana. However, the vaccination of all babies against
HVB is a strategy that the Botswana Ministry of Health and Wellness implemented in the early 2000s.
Infants are given the first dose at birth, the second at one month of age, and the last at two months of
age, thereby decreasing the chance of these children developing chronic or occult HBV infection.
The low HBV DNA levels in the HIV-positive mothers could be a result of the cross-effect of
the ART treatment that the women were receiving. In total, 75% of the women were taking ART
drugs (HAART and AZT), and the remaining 25% did not have any documented ART, but had
lower HBV DNA levels. Some of the HAART that these women were taking contain tenofovir (TDF),
emtricitabine (FTC), and lamivudine (3TC), which have anti-HBV properties, and this could explain
the low HBV DNA levels and HBeAg negativity in the HIV-positive individuals [35–37]. Tenofovir
and lamivudine are used worldwide as first-line HBV treatments due to their high barrier to resistance
and tolerability [38]. The “treat all” strategy was implemented in June 2016 in Botswana as per the
handbook of the 2016 Botswana integrated HIV clinical care guidelines [39]. The first line “treat all”
regimen contains Truvada (emtricitabine and tenofovir disoproxil fumarate) and dolutegravir (DTG).
Thus, one would expect the rates of HBV and HIV transmission to decline in the coming years.
The prevalence of the occult-infected participants was 10.4% in participants with CD4+ T-cell
counts of >500 cells/mL and 3.48% in participants with CD4+ T-cell counts of ≤500 cells/mL (Table 3).
This is contrary to what other studies have found. Several studies have shown that occult HBV
infection is more prevalent in HIV-positive people with lower CD4+ T-cell counts as opposed to people
with high CD4+ T-cell counts [40,41]. The low prevalence of occult HBV infection in the group with
CD4+ T-cell counts of <500 cells/mL could be due to the protective effect of HAART, which might
reduce the HBV DNA to undetectable levels (viral suppression) [35]. A CD4+ T-cell count cutoff of
500 cells/mL was used. This was to compare “typically” healthy HIV-positive patients with those that
are “unhealthy” and investigate associations with ART treatment and type of HBV infection [42,43].
This has also been supported by the INSIGHT START study group [44].
The genotypes detected in this study are similar to those reported by other studies in the
region [4,45]. Genotype A is more prevalent in Southern Africa, followed by D and then E. Anderson
et al. reported a higher proportion of genotype A compared to other genotypes [4]. Genotypes A, D,
and E are not linked to high levels of HBV vertical transmission, as are genotypes B and C, which
are associated with high HBV DNA levels and HBeAg positivity [46]. However, our results indicate
that in some cases, pregnant women with HBV genotypes not traditionally associated with vertical
transmission do have high HBV DNA levels, which put them at risk of transmitting HBV. The T131N
mutation that was found from our study is found on the “a” determinant region of the surface gene [47].
Computational analysis has revealed that T131N substitutions led to an insertion of an “extra” α-helix
in the “a” determinant region [47]. This has been associated with exacerbations of chronic infections
and the rescue of virion secretions [48,49].
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Table 3. Prevalence of different HBV infections and antiretroviral therapy (ART) status amongst
HIV-positive participants with low and high CD4+ T-cell counts.
CD4+ T-Cell Count
(cells/mL)
Chronic HBV
infection
(n = 382) a
Occult HBV
infection
(n = 297) b
AZT
(n = 267)
HAART
(n = 267)
> 500 3/129 (2.33%) 10/96 (10.4%) 78/96 (81.3%) 15/96 (15.6%)
≤ 500 9/253 (3.56%) 7/201 (3.48%) 124/171 (72.5%) 43/171 (25.1%)
p-value 0.511 0.01 0.110 0.07
a: number of participants with available CD4+ T-cell counts tested for chronic HBV infection, b: number of
participants with available CD4+ T-cell counts tested for occult HBV infection, AZT: Zidovudine, HAART: Highly
active antiretroviral therapy.
Despite the limited sample size and volumes used in this study, the study highlights the need
for testing pregnant women for HBV and for those testing positive to check their HBV DNA levels.
HBV-positive pregnant women with high HBV DNA levels need to be considered for further HBV
prevention of mother to child transmission (PMTCT) measures, as proposed by Wilson et al. [50].
We could not confirm whether the samples that tested HBsAg-positive were acute or chronic infections;
however, most HBV infections in sub-Saharan Africa are acquired in early childhood, and the
assumption made here was that these were chronic infections [10,51,52].
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